Assessing the Value of Next-Generation Sequencing Tests in a Dynamic Environment

American Society of Clinical Oncology Educational Book
Howard A BurrisPeter P Yu

Abstract

Next-generation sequencing (NGS)-based technology has lowered the cost of cancer testing for genomic alterations and is now commercially available from a growing number of diagnostic laboratories. However, laboratories vary in the methodologies underlying their tests, the types and numbers of genomic alterations covered by the test, and the clinical annotation of the sequencing findings. Determining the value of NGS tests is dependent on whether it is used to support clinical trials or as a part of routine clinical care at a time when both the investigational drug pipeline and the list of U.S. Food and Drug Administration-approved or Compendium-listed therapeutics is in a high state of flux. Reimbursement policy for NGS testing by the Centers for Medicare & Medicaid is evolving as the value of NGS testing becomes more clearly defined for specific clinical situations. Patient care and clinical decisions-making are dependent on the oncologist's knowledge of when NGS testing has value. Here, we review principles and practice for NGS testing in this dynamic confluence of technology, cancer biology, and health care policy.

References

Feb 6, 2002·Annals of Internal Medicine·UNKNOWN ABIM Foundation. American Board of Internal MedicineUNKNOWN European Federation of Internal Medicine
Oct 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David S HsuAnil Potti
Apr 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Elizabeth H HammondAntonio C Wolff
Jun 19, 2014·The New England Journal of Medicine·Leslie G Biesecker, Robert C Green
Aug 26, 2014·Archives of Pathology & Laboratory Medicine·Nazneen AzizKarl V Voelkerding
Nov 26, 2014·Nature Reviews. Clinical Oncology·Armand de GramontStanley R Hamilton
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria SchwaederleRazelle Kurzrock
Feb 13, 2016·The Lancet Oncology·Vinay PrasadMichael Brada
Dec 16, 2016·JAMA Oncology·Nicole M KudererC Anthony Blau
Apr 27, 2017·The New England Journal of Medicine·Mariam Jamal-HanjaniUNKNOWN TRACERx Consortium
May 28, 2017·The Oncologist·Vivek Subbiah, Razelle Kurzrock
Aug 25, 2017·Molecular Cancer Therapeutics·Aaron M GoodmanRazelle Kurzrock
Dec 21, 2017·The New England Journal of Medicine·Mark YarchoanElizabeth M Jaffee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.